Ph.D. Supervisor, Chief Physician, Director of the Hematopoietic Stem Cell Transplantation Subspecialty in the Hematology Department / Director of the Transfusion Department
Awards and Honors
- Recipient of the Anhui Provincial Science and Technology Progress Award (Second Prize) three times
- Fifth Batch of Academic and Technical Leaders in Anhui Province
- Young Leading Talent of Anhui Provincial Health Commission
- First Batch of Outstanding Technical Backbone of Anhui Provincial Hospital
Education and Work Experience
- 1986 – 1991: Bachelor's degree in Medicine, Anhui Medical University
- 2000 – 2003: Master's degree in Biochemistry and Molecular Biology, Anhui Medical University
- 2009 – 2014: Ph.D. in Pharmacology, Anhui Medical University
- 1991 – 1996: Resident Physician, Anhui Provincial Hospital
- 1997 – 2002: Attending Physician, Anhui Provincial Hospital
- 2003 – 2011: Associate Chief Physician, Anhui Provincial Hospital
- 2012 – 2017: Chief Physician, Anhui Provincial Hospital
- 2018 – Present: Chief Physician, The First Affiliated Hospital of the University of Science and Technology of China
Academic Achievements and Impact
Dr. Liu has dedicated over 20 years to the clinical and scientific research of hematological diseases and hematopoietic stem cell transplantation. She has supervised nearly 20 doctoral and master's students. Her research on hematopoietic stem cell transplantation has won three provincial second prizes for scientific and technological progress. Her primary focus is on clinical and scientific issues related to unrelated cord blood transplantation.
Dr. Liu has published over 10 papers in SCI-indexed journals such as Bone Marrow Transplant and International Journal of Cancer.
Current Projects (Main Responsibilities Only)
| Project Title | Source | Total Funding (10,000 RMB) | Duration |
| Clinical Study on Unrelated Cord Blood Transplantation with TMLI Conditioning Regimen for Refractory Severe Aplastic Anemia | Anhui Provincial Key Research and Development Plan Project | 30 | 2021-01 to 2022-12 |
| Key Issues and Interventions in Cord Blood Hematopoietic Stem Cell Transplantation | USTC New Medicine Joint Fund Innovation Team Project, Co-PI | 30 | 2018-07 to 2021-06 |
Main Research Directions (Recruitment Specialties) and Content
Clinical Medicine
1. Hematology / Hematopoietic Stem Cell Transplantation
- Study on the impact and mechanism of HCMV infection on B cell reconstitution after unrelated cord blood transplantation
- Research on the impact and mechanism of B cell reconstitution on the occurrence of graft-versus-host disease after unrelated cord blood transplantation
- Study on the impact of immune reconstitution on disease relapse after unrelated cord blood transplantation and early intervention
Representative Papers (Last Five Years)
1. Sun Z#, Liu H#, Luo C#, Geng L, Zheng C, Tang B, Zhu X, Tong J, Wang X, Ding K, Wan X, Zhang L, Yao W, Song K, Zhang X, Wu Y, Yang H, Han Y, Liu X, Zhu W, Wu J, Wang Z. Better outcomes of modified myeloablative conditioning without antithymocyte globulin vs. myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study. International Journal of Cancer. 2018; 143(3):699-708.
2. Ge J, Yang T, Zhang L, Zhang X, Zhu X, Tang B, Wan X, Tong J, Song K, Yao W, Sun G, Sun Z, Liu H. The incidence, risk factors, and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study. BMC Infectious Diseases. 2018; 18(1):654.
3. Ren Jiarong, Zhu Xiaoyu, Tang Baolin, Wan Xiang, Tong Juan, Zhang Lei, Zhang Xuhan, Song Kaidi, Yao Wen, Sun Guangyu, Liu Huilan, Sun Zimin. Efficacy analysis of unrelated cord blood transplantation for high-risk refractory AML1-ETO positive acute myeloid leukemia. Chinese Journal of Experimental Hematology. 2019; 27(4):1246-1252.
Contact Information
E-mail: huilanl@ustc.edu.cn
Phone: 0551-62283347